PMID- 25854342
OWN - NLM
STAT- MEDLINE
DCOM- 20160126
LR  - 20190816
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 16
IP  - 7
DP  - 2015
TI  - Cyr61/CCN1 overexpression induces epithelial-mesenchymal transition leading to 
      laryngeal tumor invasion and metastasis and poor prognosis.
PG  - 2659-64
AB  - BACKGROUND: To examine the expression of cysteine-rich 61 (Cyr61/CCN1) protein in 
      laryngeal squamous- cell carcinoma (LSCC) tissues, and its relationship with the 
      tumor epithelial-mesenchymal transition (EMT), invasion, metastasis, and 
      prognosis. MATERIALS AND METHODS: Immunohistochemistry was used to detect the 
      expressions of Cyr61, Vimentin (Vim), and E-cadherin (E-cad) in 88 cases of LSCC 
      tissues and 30 cases of tumor-adjacent normal tissues. Vim and E-cad were used as 
      mesenchymal and epithelial markers, respectively, to determine the relationship 
      between Cyr61 expression and the EMT of LSCC cells. In addition, clinical and 
      histopathological data were combined to analyze the relationship between the 
      positive-expression rates of Cyr61, Vim and E-cad and LSCC invasion, metastasis 
      and prognosis. RESULTS: In LSCC tissues, Vim expression rate was significantly 
      higher than that of the tumor-adjacent tissues, whereas E-cad expression rate was 
      significantly lower than that of the tumor-adjacent tissues. The Vim expression 
      rate was significantly higher in stages T3 and T4 than in stages T1 and T2 LSCC 
      tissues, whereas E-cad expression rate was significantly lower in stages T3 and 
      T4 than in stages T1 and T2 LSCC tissues. Compared to the group without lymph 
      node metastasis, the Vim expression rate was significantly higher and the E-cad 
      expression rate was significantly lower in the group with lymph node metastasis. 
      The expression rate of Cyr61 was significantly higher in LSCC tissues than in the 
      tumor-adjacent normal tissues. In addition, the Cyr61 expression rate was higher 
      in stages T3 and T4 than in stages T1 and T2 LSCC, and higher in the group with 
      lymph node metastasis than in the group without lymph node metastasis. The Vim 
      expression rate was significantly higher in the Cyr61 positive group than in the 
      Cyr61 negative group, whereas the E-cad expression rate was significantly higher 
      in the Cyr61 negative group than in the Cyr61 positive group. Survival analysis 
      indicated that survival rates of Cyr61 positive, Vim positive and E-cad negative 
      groups were significantly lower than that of Cyr61 negative, Vim negative and 
      E-cad positive groups, respectively. CONCLUSIONS: Cyr61 expression is closely 
      associated with LSCC invasion and lymph node metastasis. Overexpression of Cyr61 
      may induce EMT and therefore leads to LSCC invasion and metastasis and poor 
      prognosis. Cyr61 may become a new maker for clinical prediction of LSCC invasion 
      and metastasis and a new target for LSCC treatment.
FAU - Liu, Ying
AU  - Liu Y
AD  - Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of 
      Harbin Medical University, Harbin, China E-mail : appleliuying1979@163.com.
FAU - Zhou, Yan-Dong
AU  - Zhou YD
FAU - Xiao, Yu-Li
AU  - Xiao YL
FAU - Li, Ming-Hua
AU  - Li MH
FAU - Wang, Yu
AU  - Wang Y
FAU - Kan, Xuan
AU  - Kan X
FAU - Li, Qiu-Ying
AU  - Li QY
FAU - Lu, Jian-Guang
AU  - Lu JG
FAU - Jin, De-Jun
AU  - Jin DJ
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCN1 protein, human)
RN  - 0 (Cadherins)
RN  - 0 (Cysteine-Rich Protein 61)
RN  - 0 (Vimentin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Cadherins/metabolism
MH  - Carcinoma, Squamous Cell/mortality/*pathology
MH  - Cysteine-Rich Protein 61/*metabolism
MH  - Epithelial-Mesenchymal Transition/*physiology
MH  - Female
MH  - Head and Neck Neoplasms/mortality/*pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*mortality/*pathology
MH  - Larynx/pathology
MH  - Lymphatic Metastasis/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness/pathology
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Survival Rate
MH  - Vimentin/metabolism
EDAT- 2015/04/10 06:00
MHDA- 2016/01/27 06:00
CRDT- 2015/04/10 06:00
PHST- 2015/04/10 06:00 [entrez]
PHST- 2015/04/10 06:00 [pubmed]
PHST- 2016/01/27 06:00 [medline]
AID - 10.7314/apjcp.2015.16.7.2659 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2015;16(7):2659-64. doi: 10.7314/apjcp.2015.16.7.2659.